Item 8.01 Other Events

On September 21, 2022, DBV Technologies S.A. (the "Company") issued a press release announcing that on September 21, 2022 the Company received feedback from the U.S. Food and Drug Administration ("FDA") on the design of the new Phase 3 pivotal study for modified Viaskin Peanut - VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) ("VITESSE") in the form of a partial clinical hold. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the timing of receipt of additional details for the clinical hold of the VITESSE study from the FDA. The forward-looking statements included in this Current Report on Form 8-K are subject to a number of risks, uncertainties and assumptions, including, without limitation, the expected timing of review by governmental authorities. These statements are based only on facts currently known by the Company and speak only as of the date of this Current Report on Form 8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits

Exhibit
  No.        Description

99.1           Press Release, dated September 21, 2022

 104         Cover Page Interactive Data File (the cover page XBRL tags are
             embedded within the inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses